Jennifer Pietenpol, Ph.D., B.F. Byrd Jr. Professor of Oncology and director of Vanderbilt-Ingram Cancer Center, has been named an at-large member of the National Cancer Policy Forum, an advisory group of the Institute of Medicine (IOM) of the National Academies.

Tennessee-based congressional staff members spent the day on campus June 25 to learn firsthand about Vanderbilt services and resources.

New Vanderbilt research suggests patients with advanced melanoma — the most deadly form of skin cancer — could safely benefit from a combination of immunotherapy and targeted therapies aimed at specific gene mutations.

My Cancer Genome, an online precision cancer medicine tool developed by researchers at Vanderbilt-Ingram Cancer Center, has unveiled an updated free mobile app that provides even more information about genetic alterations in various types of cancer and the therapies available to treat those alterations.

Using enhanced gene mutation testing to provide precision therapy for cancer patients was one of the themes at the annual Vanderbilt-Ingram Cancer Center (VICC) scientific retreat, held May 15 at the Vanderbilt Student Life Center.

The contractile machinery inside tumor cells increases invasive properties, suggesting it might be a good target to inhibit cancer cell spread.